Obstetric and Gynecologic Imaging

What Is the Best Follow-Up Imaging for a Likely Benign Adnexal Mass in a Postmenopausal Patient?

·
What Is the Best Follow-Up Imaging for a Likely Benign Adnexal Mass in a Postmenopausal Patient?

A 68-year-old female, postmenopausal for over a decade, returns for a follow-up visit. Six months ago, during a computed tomography (CT) scan for an unrelated issue, an incidental 3 cm simple-appearing cyst was noted on her left ovary. It had all the characteristics of a benign finding, and she remains asymptomatic. Now, you must decide on the appropriate surveillance imaging to ensure its stability without exposing her to unnecessary radiation or cost. This article details the American College of Radiology (ACR) guided workflow for this specific clinical question: follow-up of a likely benign adnexal mass in a postmenopausal patient. For this scenario, the ACR rates `US duplex Doppler pelvis` as Usually Appropriate.

Who Fits This Clinical Scenario for Adnexal Mass Follow-Up?

This guidance is specifically for postmenopausal women who have a previously identified adnexal mass with imaging features strongly suggesting a benign etiology. The classic example is a simple, thin-walled, anechoic cyst without solid components or significant internal vascularity. The patient must have no acute symptoms such as severe pelvic pain, fever, or other signs suggesting ovarian torsion, hemorrhage, or infection. This workflow applies only to surveillance imaging—that is, a follow-up study to assess for interval change, not the initial diagnostic workup of a newly discovered mass.

This pathway should not be applied to patients who fall into other clinical categories, as their management differs significantly:

  • Premenopausal Patients: The differential diagnosis and risk stratification for adnexal masses are different in premenopausal women due to cyclic physiologic changes. This guidance is not for them.
  • Initial Imaging Workup: If a mass is clinically suspected but has not yet been imaged, the workflow for initial characterization should be followed.
  • Indeterminate or Suspicious Masses: If the initial imaging determined the mass was indeterminate or suspicious for malignancy (e.g., containing solid components, thick septations, or significant vascularity), a more aggressive imaging and management pathway is warranted, and this surveillance protocol is inappropriate.

What Diagnoses Are You Monitoring in This Scenario?

In this follow-up setting, the primary goal is to confirm stability, which provides strong evidence of a benign process. While the pre-test probability of malignancy is low for a simple-appearing cyst, surveillance is performed to confidently exclude the small possibility of a developing malignancy.

Simple Ovarian or Paraovarian Cyst
This is the most common and expected finding. Simple cysts are fluid-filled sacs that are exceedingly common and overwhelmingly benign in postmenopausal women, particularly when small. Follow-up imaging serves to confirm that the cyst has not grown significantly or developed complex features. Paraovarian cysts, arising adjacent to the ovary, are also almost universally benign.

Hydrosalpinx
A fluid-filled, dilated fallopian tube can be mistaken for an ovarian cyst on initial imaging. Its characteristic tubular or serpentine shape is often better delineated on follow-up ultrasound, confirming its extra-ovarian origin and benign nature.

Hemorrhagic Cyst
While much more common in premenopausal women, low-level hemorrhage can occur in a benign cyst in a postmenopausal patient. Follow-up ultrasound is excellent for demonstrating the expected evolution and eventual resolution of hemorrhagic products, distinguishing them from a worrisome solid nodule.

Early-Stage Ovarian Malignancy (the “Rule-Out” Diagnosis)
This is the most consequential, albeit least likely, diagnosis being excluded. The fundamental purpose of surveillance is to detect morphologic changes that would be concerning for malignancy. These red flags include the development of a new solid mural nodule, the appearance of thick or irregular septations, a significant increase in size, or the development of internal blood flow on Doppler imaging. Identifying these changes early is critical for prompting further workup.

Why Is Pelvic Ultrasound the Recommended Follow-Up Study?

The ACR designates several forms of pelvic ultrasound, including `US duplex Doppler pelvis`, as Usually Appropriate for this scenario because it directly and safely answers the clinical question: has the likely benign mass changed?

The rationale is rooted in ultrasound’s unique strengths for this application. First, it offers outstanding spatial resolution for characterizing the key morphologic features of an adnexal mass. A high-frequency transvaginal probe can clearly delineate the thin, smooth wall of a simple cyst and confirm its anechoic (black) fluid content, providing high confidence in its benign nature. Second, the inclusion of Duplex Doppler is crucial. It assesses for the presence of internal blood flow. The absence of vascularity within a cyst or its wall is a highly reassuring feature, whereas the detection of flow within a solid-appearing component is a primary indicator of potential malignancy.

Most importantly, ultrasound is a non-invasive modality that uses no ionizing radiation (Relative Radiation Level: O, 0 mSv). This makes it the ideal tool for serial follow-up, as it avoids the cumulative radiation dose that would be incurred with other modalities. It is also widely available and less costly than cross-sectional alternatives.

Why Alternative Studies Are Rated Lower for This Scenario

  • MRI pelvis without and with IV contrast is rated as May be appropriate. MRI provides excellent soft-tissue characterization and is a superior problem-solving tool if the ultrasound findings are equivocal or indeterminate. However, for the routine follow-up of a mass that already appears benign on prior imaging, its higher cost and lower availability make it an unnecessary second-line choice. It is best reserved for when ultrasound raises new questions.
  • CT pelvis with IV contrast is rated as Usually not appropriate. CT exposes the patient to significant ionizing radiation (Relative Radiation Level: ☢☢☢, 1-10 mSv) and offers inferior soft-tissue contrast resolution for evaluating internal ovarian architecture compared to ultrasound or MRI. Its use for simple surveillance of a benign-appearing cyst is not justified.

What Is the Downstream Workflow After a Follow-Up Pelvic Ultrasound?

The results of the follow-up ultrasound will guide the next steps in a clear, evidence-based manner. The decision tree branches based on whether the mass is stable or has changed.

  • If the mass is stable or has decreased in size: This is the most common outcome and provides strong reassurance of a benign etiology. For simple cysts under a certain size threshold (often cited as 5 cm, though institutional and society guidelines vary), many clinicians will recommend discontinuing further imaging follow-up. For slightly larger but still simple-appearing cysts, another follow-up in 12 months may be considered before ceasing surveillance.
  • If the mass has resolved: No further follow-up is necessary.
  • If the mass has grown significantly or developed suspicious features: If the follow-up ultrasound reveals an increase in size, or more importantly, the development of new solid components, thickened septations, or internal vascularity, the mass is no longer considered “likely benign.” It is now reclassified as indeterminate or suspicious. This finding fundamentally changes the management pathway. The next appropriate step is to order a problem-solving study, which is typically an `MRI pelvis without and with IV contrast`. This will provide a more detailed characterization to guide a subsequent referral to a gynecologic oncologist.

Pitfalls to Avoid (and When to Get Help)

When managing this common clinical scenario, several pitfalls can lead to suboptimal care. Be mindful of the following:

  • Inappropriate Modality Choice: Avoid ordering a CT scan for routine surveillance. The radiation exposure is unnecessary, and the diagnostic information for ovarian characterization is inferior to ultrasound.
  • Misclassifying the Patient: Ensure the patient is truly postmenopausal and the initial finding was genuinely “likely benign.” Applying this conservative follow-up strategy to a premenopausal patient or a patient with an indeterminate mass is incorrect.
  • Ignoring Incidental Findings: While focused on the adnexal mass, the radiologist may identify other pelvic findings. Be sure to review the entire report and address any other clinically significant incidentalomas.
  • Over-Surveillance: For small, classic simple cysts that have been stable over one or two follow-up intervals, continuing to image them annually for years may represent over-utilization. Know the guideline-recommended stopping points.

If the follow-up ultrasound report describes any new, complex, or solid features, or if the interpreting radiologist expresses uncertainty, this is a clear trigger to escalate care. The next step is typically consultation with or referral to a gynecologist and ordering a pelvic MRI for further characterization.

Related ACR Topics and Tools

This article covers one specific variant within the broader ACR Appropriateness Criteria for adnexal masses. For a comprehensive overview of all related scenarios, from initial workup to management of suspicious lesions, please see our parent guide. The tools below can help you apply these guidelines in your daily practice.

Frequently Asked Questions

How often should a simple-appearing postmenopausal adnexal mass be followed with ultrasound?

The frequency and duration of follow-up depend on the size and specific features of the mass. For small (1-5 cm) simple cysts, a common approach is an initial follow-up ultrasound in 6-12 months. If stable, a second follow-up in another year may be performed, after which surveillance is often discontinued. Guidelines from organizations like the American College of Obstetricians and Gynecologists (ACOG) and the Society of Radiologists in Ultrasound (SRU) provide specific size-based recommendations.

Is a transvaginal ultrasound always necessary for follow-up?

For visualizing the ovaries and adnexa, transvaginal ultrasound (TVUS) provides significantly higher resolution and more diagnostic detail than a transabdominal-only approach. While a transabdominal scan is often performed first for a broader overview of the pelvis, TVUS is considered essential for the definitive characterization and follow-up of an adnexal mass. The ACR lists both approaches, as well as the combination, as ‘Usually Appropriate’.

What if the patient cannot tolerate a transvaginal ultrasound?

If a patient cannot tolerate a transvaginal ultrasound, a transabdominal ultrasound is the primary alternative. However, it’s important to recognize its limitations, especially in patients with a large body habitus or a retroverted uterus. If the transabdominal images are suboptimal and do not adequately characterize the mass, an MRI of the pelvis without and with contrast may be necessary as a problem-solving tool.

Does the CA-125 tumor marker have a role in this specific follow-up scenario?

For a simple-appearing cyst in an asymptomatic postmenopausal woman, a CA-125 test has a low positive predictive value and is not routinely recommended as part of surveillance. Its utility increases significantly if the mass has complex or solid features on imaging, at which point it becomes an important part of the workup in conjunction with a referral to a gynecologic oncologist.

What if the ovary is not visualized on the follow-up ultrasound?

In postmenopausal women, the ovaries can atrophy and become difficult to visualize, especially on transabdominal ultrasound. If a previously seen benign-appearing cyst is on an ovary that cannot be confidently identified on a high-quality transvaginal scan, it often implies the ovary is small and atrophic, and the cyst may have resolved. If there is high clinical concern or the prior study was indeterminate, a pelvic MRI may be considered to definitively locate the ovary and exclude a persistent mass.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026